The Process of How Elderly Patients with Lung Cancer Who Are Receiving Molecularly Targeted Therapy with Oral Agents Establish Self-Management

Purpose: In Japan, many elderly cancer patients are receiving chemotherapy using oral molecularly targeted drugs. They receive treatment in outpatient setting and have a need to self-manage at home. The purpose of this study was to clarify how elderly patients with lung cancer who are undergoing treatment with molecularly targeted drugs in outpatient setting establish self-management. Methods: The study used Kinoshita’s Modified Grounded Theory. Semi-structured interviews were conducted with 17 patients (eight males and nine females). Results: This study identified six categories: Accepting life with cancer, Maintaining activities of daily living without feeling shackled by cancer, Reconsidering how to continue being themselves in daily life until life comes to an end, Using trial and error to integrate treatment and daily living, Formulating their criteria for continuing treatment, and Obtaining help from caregivers. Conclusion: The self-management process in elderly patients consisted of maintaining treatment and integrating treatment with daily living. And they are exploring the effects of treatment and side effects in order to live their own life. Implications for Nursing: In many elderly patients with lung cancer the purpose of treatment is curative extension of survival and improved quality of life. Our findings suggest that is important we help patients to identify how patients want to live, identify ways to improve their quality of life, and share the goals of treatment between the patient and the caregiver.

Gemcitabine plus carboplatin used as induction regimen for elderly patients with locally advanced unresectable non-small cell lung cancer

Objective:The purpose of this study was to evaluate the efficacy and safety of gemcitabine(GEM) and carboplatin(CBP) used as induction regimen in the treatment of elderly patients with locally advanced unresectable non-small cell lung cancer(NSCLC).Methods:Seventy-eight cases of elderly patients have been cytologically and pathologically confirmed with locally advanced unresectable NSCLC,the age of the patients ranged from 65 to 75 years.The patients were treated with the combined regimen of gemcitabine and cisplatin.GEM 1000 mg/m2 intravenously injected by drip on the 1st,8th day and the dosage of CBP was AUC 4 that was used on the 1st day,21 days apart to each cycle,most patients received 2 cycles.Treatment response was evaluated according to the criteria of RECIST(Response Evaluation Criteria in Solid Tumor),the side effect of the regimen was judged based on WHO criteria.Results:Seventy-eight patients were evaluated and received a total of 156 cycles chemotherapy.There were no complete regression that could be observed,but 32 cases had partial regression(PR),37 cases with no change(NC) and 9 cases with progression disease(PD).The overall response rate was 41.0%.The main side effects were hematological toxicity.Conclusion:The GC regimen could be used as induction treatment for elderly patients with locally advanced unresectable NSCLC,and the regimen could be well tolerated and is safe in terms of side effects.

Clinical observation of docetaxel in treating advanced non-small cell lung cancer in the elderly patients

Objective:The aim of our study was to evaluate the clinical efficacy and side effects of docetaxel as single chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC). Methods: Forty-two elderly patients with advanced NSCLC who were chemotherapy-naive were enrolled in this study. Docetaxel at the doses of 70 mg/m2 was administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results: Among 42 patients, 40 could be evaluated, 1 complete response (CR), 9 partial response (PR), 13 stable disease (SD), 17 progress disease (PD). The overall response rate (CR+PR) was 35% and disease control rate (CR+PR+SD) was 57.5%. The median time to progress (TTP) was 4.2 months, median survival time was 6.1 months and 1-year survival rate was 35.8%. The main toxicity was myelosuppression and decreasing platelet. Conclusion: Single agent docetaxel for elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach with a low toxicity level.

The Results Observation on Adjuvant Chemotherapy with Microwave Hyperthermia and Stereotactic Radiotherapy in Retreated Elderly Patients with Advanced (III/IV Stage) Lung Cancer

Objective: To evaluate the significance of adjuvant chemotherapy and radiotherapy (Gamma-knife) in the elderly patients with retreated advance lung cancer. Methods 83 patients (age 50 to 81 years) with retreating advanced (III/IV stage) lung cancer were divided into three groups according to patients received treating by different methods. The cases were treated by synchronous chemo-radiotherapy (A group), sequentially chemo-radiotherapy (B group) and continuous systematized chemotherapy alone (C group). The systemic 3-dimensional orientation apparatus was used in radiotherapy. The chemotherapy regimen in combined radiotherapy was given by common first line regimen on lung cancer. The regimen of chemotherapy combated with whole body hyperthermia by using micro-wave on abodeman about 2 or 3 line was used in C group only. Results: The overall responses rates (RR) of A, B and C groups were 17.1%, 11.5% and 31.8%, but it was non-significance difference (P > 0.05). Overall responses rates (RR) of III and IV stage groups were 18.2% and 20.0%. The average overall survival time (OS) and median survival time (MST) of the patients treated by chemotherapy (C group) were highest about 14.2 and 9.3 months (respectively at A group 6.7 and 6.0 months. P < 0.01), in which B group was longer than A group (P < 0.05), and 95.5% CI value was not overlap. The total survival time of postoperative patients was longer in the various groups by different treated than that in non-operations. Conclusion: The rates (RR) of III and IV stage groups were non-significance difference. The higher of ORR, OS and MST in a few patients of re-treated advanced lung cancer was presented in case with treated by continuous system chemotherapy. There were survival superiority in initial postoperative patients groups by different treated. It is a profitable and effect treatment that the pure reasonable systemic chemotherapy was used for elderly case with advanced retreated lung cancer.

Elderly Lung Cancer Patients and Radiochemotherapy: A Review

More than 60% of lung cancer patients in Europe and the USA are older than 65 years at the time of diagnosis. Despite this, elderly patients are generally under-represented in clinical trials. That being so, a general consensus on how to treat elderly patients is still far from being achieved. In this review, we address some of the issues and challenges surrounding the treatment of older cancer patients and radiochemotherapy. We discuss the existing evidence related to radio-chemotherapy in the elderly, focusing primarily on the lung cancer (NSCLC and SCLC) most commonly seen in older patients, and making general treatment recommendations.

Acceptance on colorectal cancer screening upper age limit in South Korea

BACKGROUND The Korea National Cancer Screening Program currently provides screening for colorectal cancer(CRC)for adults older than 50 years with no upper age limit.In general,people are likely to only pay attention to the benefits of cancer screening and to neglect its risks.Most consider the benefits of cancer screening as being far greater than the risks and are unaware that any potential benefits and harms can vary with age.AIM To report acceptance of an upper age limit for CRC screening and factors associated therewith among cancer-free individuals in Korea.METHODS The present study analyzed data from the Korea National Cancer Screening Survey 2017,a nationally representative random sample of 4500 Korean individuals targeted for screening for the five most common types of cancer.A total of 1922 participants were included in the final analysis.The baseline characteristics of the study population are presented as unweighted numbers and weighted proportions.Both univariate and multivariate logistic regression models were developed to examine factors related with acceptance of an upper age limit for CRC screening;subgroup analysis was also applied.RESULTS About 80%(1554/1922)of the respondents agreed that CRC screening should not be offered for individuals older than 80 years.Specifically,those who had never been screened for CRC had the highest acceptance rate(91%).Overall,screening history for CRC[screened by both fecal occult blood test and colonoscopy,adjusted odds ratio(aOR)=0.33,95%CI:0.22-0.50]and other cancers(aOR=0.55,95%CI:0.34-0.87),as well as a family history of cancer(aOR=0.66,95%CI:0.50-0.87),were negatively associated with acceptance of an upper age limit for CRC screening.In contrast,metropolitan residents(aOR=1.86,95%CI:1.29-2.68)and people who exercised regularly(aOR=1.42,95%CI:1.07-1.89)were more likely to accept an upper age limit.After subgrouping,we found gender,marital status,and lifetime smoking history among never-screened individuals and residential region,family history of cancer,and physical activity among never-screened individuals to be associated with acceptance of an upper age limit.CONCLUSION This study describes acceptance of an upper age limit for CRC screening and factors associated with it,and provides perspectives that should be considered,in addition to scientific evidence,when developing population-based cancer screening policies and programs.

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer:a retrospective analysis

Bevacizumab,an anti-VEGF monoclonal antibody,has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC(ns-NSCLC).However,the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation.Thus,59 patients were included in the present retrospective study,22 patients in the bevacizumab plus pemetrexed and platinum(B+PP)group,and 37 patients in the pemetrexed and platinum(PP)group.For the entire cohort of patients,the median OS was 33.3 months,and the 1-year and 2-year overall survival rates were 88.5%and 67.8%,respectively.The median OS and 1-year and 2-year OS rates were 20.5 months,70.3%and 0%,respectively,in the B+PP group and 33.4 months,97.0%and 89.4%,respectively,in the PP group(P<0.001).The incidence of grade≥3 adverse events was higher in the B+PP group than in the PP group(27.3%vs.10.8%,respectively;P=0.204).Univariate and multivariate analyses suggested that the receipt of≥5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS,whereas the addition of bevacizumab was an unfavorable prognostic factor.With increased toxicities,the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.

An Elderly Patient with Advanced Lung Cancer Achieved Long-Term Survival Using Chinese Medicine:An Alternative Treatment Strategy for Cancer Patients Aged 80 or Older without A Tissue Confirmed Diagnosis

Lung cancer is the leading cause of cancerrelated mortality in China.（1＇2） Meanwhile, the average life expectancy in the aging population has increased from 46 years in 1950 to 75 years in 2010.

四逆散联合桃红四物汤加减治疗老年早期肺癌胸腔镜术后急性胸痛患者的临床疗效及对其生活质量的影响

目的探讨四逆散联合桃红四物汤加减治疗老年早期肺癌胸腔镜术后急性胸痛患者的临床疗效及对其生活质量的影响。方法选取2019年1月-2020年6月期间在保定市第二中心医院接受治疗的86例非小细胞肺癌患者,采用随机数字表法分为对照组和观察组,每组各43例。对照组患者胸腔镜术后给予尼美舒利胶囊口服治疗,观察组患者胸腔镜术后给予四逆散合桃红四物汤加减方治疗。治疗2周后,观察比较两组患者临床疗效、不良反应情况,治疗前后疼痛状况评分[数字分级评分法评分(Numeric rating scale,NRS)、疼痛视觉模拟评分法评分(Visual analogue scale,VAS)]、咳嗽评分[咳嗽积分和咳嗽视觉模拟评分法(Visual analogue scale,VAS)]、EORTC QLQ-C30(version 3)生活质量量表评分。结果治疗后观察组总有效率93.02%(40/43)明显高于对照组74.42%(32/43),差异有统计学意义(P<0.05)。治疗后两组患者疼痛状况NRS、VAS评分均较治疗前明显降低,差异有统计学意义(P<0.01);且观察组疼痛状况NRS、VAS评分均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者咳嗽状况咳嗽积分、咳嗽VAS评分均较治疗前明显降低,差异有统计学意义(P<0.01);且观察组咳嗽状况咳嗽积分、咳嗽VAS评分均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者角色功能、躯体功能、认知功能、情绪功能、社会功能及总体健康状况评分均较治疗前升高,差异有统计学意义(P<0.01),两组患者恶心呕吐、疼痛评分均较治疗前降低,差异有统计学意义(P<0.01);且观察组角色功能、躯体功能、认知功能、情绪功能、社会功能及总体健康状况评分均明显高于对照组,观察组恶心呕吐、疼痛评分均明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组患者肾功能、肝功能、血常规、心电图、尿常规、便常规等安全性指标均未出现明显异常,也未发生与药物使用相关的严重不良反应。结论四逆散合桃红四物汤加减方能够有效缓解早期肺癌患者胸腔镜术后急性疼痛程度和咳嗽程度,缩短疼痛治疗时间,减少西医止痛药物使用剂量,改善患者生活质量,安全且有效。

射波刀治疗老年早期非小细胞肺癌的治疗效果与安全性

目的探讨射波刀治疗老年(≥75岁)早期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的有效性与安全性,并与<75岁患者的结果对比。方法回顾性分析2013年1月至2019年10月济南市解放军第960医院收治的75例早期(T1-2N0M0)NSCLC患者。<75岁患者32例(42.7%),≥75岁患者43例(57.3%)。所有患者剂量方案为45~66Gy/3~8F,60%~85%等剂量线作为处方剂量包绕计划靶区(planning target volume,PTV),每日1次,每周5次。比较两组患者临床治疗效果、生存状况及治疗毒性,并分析影响≥75岁患者生存期的因素。结果<75岁和≥75岁患者疾病控制率分别为96.9%和93.0%(P>0.05)。5年局部控制率(local control,LC)、无进展生存率(progression-free survival,PFS)和癌症特异性生存率(cancer-specific survival,CSS)分别为70.9%和85.4%,58.5%和54.4%,70.4%和64.5%,差异均无统计学意义(P>0.05)。但≥75岁患者的生存率(overall survival,OS)明显低于<75岁患者,5年OS分别为49.2%和68.2%(P<0.05)。两组患者的治疗并发症比较,差异无统计学意义(P>0.05)。多因素分析发现生物等效剂量(biologic effective dose,BED)是影响老年患者OS的独立因素。结论采用射波刀对不适合手术的老年早期NSCLC患者行立体定向放射治疗是一种安全有效的治疗方式。

肺癌患者胸腔镜术后早期活动现状及其相关影响因素分析

目的 探析肺癌患者胸腔术厚早期活动现状现状,并分析相关影响因素。方法 前瞻性分析,纳入2020年1月-2022年1月医院收治的行胸腔镜手术治疗的肺癌患者70例作为研究对象,术后持续观察72h,制作基线资料调查表,查阅并记录患者入院时的临床资料,采用早期活动评估量表评估,以线性回归分析肺癌患者胸腔镜术后早期活动现状相关影响因素。结果 经评估70例患者早期活动评分20-38分,平均得分范围(30.50±4.50)分;不同年龄、疼痛程度、负面情绪以及希望水平的肺癌患者胸腔镜术后早期活动评分比较(P<0.05);后进一步经多元线性回归分析结果 显示,年龄、疼痛程度、负面情绪以及希望水平是肺癌患者胸腔镜术后早期活动现状相关影响因素(P<0.05)。结论 年龄、疼痛程度、负面情绪以及希望水平是肺癌患者胸腔镜术后早期活动现状相关影响因素。

An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma:a rare case report and review of the literature

We report the case of a 90-year-old female patient who was suffering from c-ros oncogene 1(ros-1)rearrangement adenocarcinoma and breast cancer.After about 14 months of a reduced dose of crizotinib treatment,she had a stable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1).This patient’s case demonstrates that ros-1 rearrangements are not limited to patients of young age.In addition,this case indicates that crizotinib,as second-line,or even first-line,treatment may be effective and manageable in elderly patients.Furthermore,for elderly patients carrying a ros1 fusion,a reduced dose of crizotinib may be efficacious rather than a resistance factor.Based on our findings,we recommend that elderly patients with advanced lung adenocarcinoma should be considered for inclusion in molecular screening for ros-1 translocation,especially for never-smokers negative for epidermal growth factor receptor(egfr)mutation and the fusion between echinoderm microtubule associated protein-like 4(EML4)and anaplastic lymphoma kinase(ALK).This deserves attention because the population is aging,with increasing incidence and morbidity of multiple primary malignant tumors.Neglect of breast nodules at the onset is one of the limitations of our case,as combination of primary lung cancer with breast cancer is common.Above all,use of antiestrogens before and after the diagnosis of non-small-cell lung cancer is related to a reduced risk of lung cancer mortality.Therefore,careful attention should always be paid to these cases.

Th1/Th2细胞因子及nCD64指数在肺癌早期感染监测与治疗中的应用价值

目的评估Th1/Th2细胞因子及中性粒细胞CD64(neutrophil CD64,nCD64)指数在肺癌早期感染监测与治疗中的应用价值。方法选取2020年5月至2022年4月福建医科大学附属南平第一医院收治的160例肺癌患者作为肺癌组,同时选取健康体检人员80人作为正常对照组。肺癌组又分为肺癌感染组(n=80)和肺癌非感染组(n=80)。肺癌感染组采用经验性抗感染药物及化学药物治疗,肺癌非感染组只采用化学药物治疗。在治疗第0、7、14、21天后检测各组患者白细胞介素(interleukin,IL)-2、IL-4、IL-6、IL-10、γ干扰素(interferon-gamma,IFN-γ)、肿瘤坏死因子(tumor necrosis factor,TNF-α)、CD64水平,并计算nCD64指数值。结果肺癌感染组中,白色念珠菌的感染率最高,占总数的67.5%。与正常对照组相比,在治疗后第0、7天时,肺癌非感染组的IL-2、TNF-α、IFN-γ均显著降低(P<0.05),IL-4、IL-6、IL-10、n CD64指数均显著升高(P<0.05);治疗第14天时,肺癌非感染组的IL-2、TNF-α、IFN-γ均显著降低,IL-6、IL-10、n CD64指数均显著升高(P<0.05);治疗第21天时,肺癌非感染组与正常对照组各项指标比较,差异均无统计学意义(P>0.05)。与肺癌非感染组比较,在治疗后第0、7、14天时,肺癌感染组IL-2和IFN-γ均显著降低(P<0.05),IL-4、IL-6、IL-10、n CD64指数均显著升高(P<0.05);治疗第21天时,肺癌非感染组与肺癌感染组组各项指标比较,差异均无统计学意义(P>0.05)。nCD64指数的曲线下面积(area under the curve,AUC)为0.925,95%置信区间(confidence interval,CI):0.875~0.975;IL-6的AUC为0.889,95%CI:0.835~0.943。nCD64指数和IL-6的截断值分别为5.25pg/ml、11.45pg/ml,敏感度分别为95.6%、92.3%,特异性分别为83.7%、78.9%,诊断效能较好。结论n CD64、IL-6可作为肺癌患者早期感染指标,且nCD64指数的预测效能优于IL-6。

射波刀治疗老年早期肺癌患者的初步临床疗效观察

目的:探讨采用射波刀(CyberKnife)立体定向放射治疗技术治疗70岁以上老年早期肺癌患者的有效性和安全性。方法:回顾性分析天津医科大学附属肿瘤医院放疗科2006年11月至2010年9月间34例不能手术的老年早期肺癌患者(T_1N_0M_020例,T_2N_0M_014例),中位年龄78(70～88)岁,18例患者采用肿瘤内植入1～2枚金标的呼吸同步追踪技术(Synchrony),16例患者采用椎体追踪技术(X-Sight)。处方剂量45～60 Cy,中位剂量60 Gy,分3～6次给予。结果:25例病变完全缓解(73.5%),9例部分缓解(26.5%)。中位随访期29(11～59)个月,原发肿瘤局部控制率97.1%,1、2、3年无进展生存率分别为85.3%、81.6%、70.0%,总生存率分别为97.1%、86.6%、80.0%。31例患者(91.1%)出现治疗后的轻度乏力,15例患者(44.1%)发生Ⅰ～Ⅱ级放射性肺炎,未发现Ⅲ级及以上的不良反应。1例患者(2.9%)在经胸腔穿刺植入金标后发生严重气胸,经胸腔闭式引流后缓解。结论:射波刀立体定向放射治疗技术疗效确切,不良反应轻,为无法手术的老年早期肺癌患者的较好选择。

NP方案化疗治疗老年晚期非小细胞肺癌

[目的]评价NP方案治疗老年非小细胞肺癌疗效、毒性反应及其耐受性。[方法]以国产长春瑞宾（NVB）联合顺铂（DDP）方案治疗老年晚期非小细胞肺癌（NSCLC）23例,NVB 25 mg/m^2静脉滴注,第1、8天;DDP 60mg/m^2,第1-3天静脉滴注,每21-28天重复,每周期观察其不良反应,每两周期评价疗效。[结果]本组共完成化疗67个周期,中位周期数2个（2-6个）,总有效率26%,中位生存期10.3个月,1年生存率34.7%。最常见的毒性反应为白细胞减少,发生率为82.6%。胃肠道反应较轻。未见明显肝肾功能损害。[结论]老年非小细胞肺癌患者对于NP方案耐受良好,毒性反应较轻,近期疗效令人满意。

胸腔镜肺段切除术和肺叶切除术治疗老年早期非小细胞肺癌患者的疗效比较

目的探讨胸腔镜肺段切除术和胸腔镜肺叶切除术治疗老年早期非小细胞肺癌(NSCLC)患者的疗效差异。方法回顾性分析接受胸腔镜切除手术(VATS)的82例老年早期NSCLC患者的临床资料,将34例接受胸腔镜肺段切除术的患者纳入肺段切除组,将48例接受胸腔镜肺叶切除术的患者纳入肺叶切除组。比较2组患者围术期相关指标,并比较术后12个月随访结果及肺功能检测情况。结果2组手术出血量、淋巴结清扫数、术后引流量、住院时间和住院费用比较,差异均无统计学意义(P>0.05);肺段切除组手术耗时(170.43±25.90)min,显著长于肺叶切除组的(158.70±22.76)min(P<0.05);肺段切除组近期手术并发症发生率为8.82%,低于肺叶切除组的12.50%,但差异无统计学意义(P>0.05);术后12个月随访显示,2组均未出现肿瘤复发、转移或死亡病例,而肺段切除组患者肺功能指标用力肺活量(FVC)、第1秒用力呼气容积(FEV 1)和最大通气量(MVV)的下降率均显著低于肺叶切除组(P<0.05)。结论胸腔镜肺段切除术和肺叶切除术均是治疗老年早期NSCLC患者的有效微创术式,二者近期手术疗效相近,但前者对患者肺功能的影响较小,尤其适用于肺功能较差或不耐受肺叶切除的老年NSCLC患者。

培美曲塞二钠治疗老年中晚期非小细胞肺癌的近期疗效分析

目的观察培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法34例Ⅲ-Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。培美曲塞联合顺铂治疗后评价疗效。结果34例患者均可评价,获得完全缓解0CR3例,部分缓解PR12例,有效率为44.1%（15/34）。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论培美曲塞联合顺铂治疗老年中晚期NSCLC有较好疗效,可明显改善患者生存质量,,毒副反应轻,易于耐受。

电视胸腔镜手术治疗老年早期肺癌的临床体会

目的:总结电视胸腔镜手术(VATS)治疗老年早期肺癌患者的经验。方法:回顾性分析21例65岁以上老年肺癌患者VATS手术治疗的临床资料。结果:治愈21例,无一例死亡。结论:VATS切口小,损伤小,患者痛苦少,对肺功能影响小,对老年患者是一个安全的选择,通过充分的术前准备,积极防治术后并发症,可以获得相对良好的治疗效果。

重组人血管内皮抑制素注射液联合NP方案治疗晚期非小细胞肺癌的疗效观察

目的观察了解重组人血管内皮抑制素注射液（恩度）联合NP方案治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法37例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。恩度联合顺铂治疗2～4个周期后评价疗效。结果37例患者中CR4例，PR15例，有效率51．4％（19／37）。中位TTP为6．8个月，1年生存率为43．2％。最主要的毒副反应为白细胞及血小板降低，但均可耐受。结论恩度联合NP方案治疗老年晚期NSCLC有较好疗效，可明显改善患者生存质量，毒副反应轻，易于耐受。

多西紫杉醇单药化疗在老年中晚期非小细胞肺癌的近期疗效分析

目的观察了解多西紫杉醇单药化疗在老年晚期非小^(NSCLC)的临床疗效和毒性反应。方法 29例Ⅲ~Ⅳ期NSCLC老年患者均经病理组织学和(或)细胞学检查确诊。多西紫杉醇单药治疗后评价疗效。结果 29例患者均可评价,获得CR2例,PR10例,有效率41.4%(12/29)。1年生存率为48.3%(14/29)。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论多西紫杉醇单药化疗治疗老年晚期NSCLC有较好疗效,可明显改善患者生存质量,毒副反应轻,易于耐受。